Lantern Pharma Unveils AI Module to Enhance Cancer Combination Therapies Development

Lantern Pharma (NASDAQ: LTRN), a leader in AI-driven oncology drug development, has announced the introduction of a novel AI-powered module within its RADR(R) platform. This innovative tool is designed to predict the effectiveness of combination therapies that utilize DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis). The development is supported by a comprehensive analysis of 221 clinical trials, showcasing the module's ability to facilitate the precise, biomarker-guided design of cancer treatment regimens. This advancement is expected to cut development time and costs by up to one-third, marking a significant leap forward in oncology research.

The newly launched module has already played a pivotal role in the design of Lantern Pharma's FDA-cleared Phase 1B/2 trial for triple-negative breast cancer, which combines LP-184 and olaparib. This demonstrates the practical application and potential of the AI module in real-world clinical settings. Lantern Pharma is actively seeking licensing and commercialization opportunities to expand the use of this system across various oncology indications, further underscoring the transformative impact of AI in drug development.

The RADR(R) platform, Lantern Pharma's proprietary AI and machine learning system, is at the heart of this innovation. It leverages over 200 billion oncology-focused data points and a library of more than 200 advanced machine learning algorithms to address challenges in oncology drug development. This has enabled Lantern Pharma to accelerate the development of its drug pipeline, advancing from initial AI insights to first-in-human clinical trials in just 2-3 years, with an average cost of approximately $2.5 million per program. The launch of the AI module for combination therapies represents a milestone in the company's mission to revolutionize the cost, pace, and timeline of oncology drug discovery and development.